Clostridium difficile: controversies and approaches to management

@article{Bauer2009ClostridiumDC,
  title={Clostridium difficile: controversies and approaches to management},
  author={M. Bauer and J. V. van Dissel and E. Kuijper},
  journal={Current Opinion in Infectious Diseases},
  year={2009},
  volume={22},
  pages={517–524}
}
Purpose of review The increasing incidence of Clostridium difficile infection (CDI) is confronting us with two major problems in CDI management that presently remain unsolved: refractoriness to therapy and recurrence of disease. This review focuses on recent insights in antimicrobial therapy of CDI, as well as advances in alternative treatment modalities. Recent findings In severe CDI, oral vancomycin has shown its superiority over metronidazole in two independent trials. Of new antimicrobials… Expand
Current State of Clostridium difficile Treatment Options
TLDR
Treatment of patients with multiple CDI recurrences and those with severe complicated CDI is based on limited clinical evidence, and new treatments or strategies are needed. Expand
Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options
TLDR
The use of selected monoclonal antibodies directed against C. difficile toxins in addition to standard therapy is a new, promising approach for the treatment of recurrent cases and vaccination could be an additional weapon against CDI. Expand
Clostridium difficile infection: epidemiology, risk factors and management
TLDR
The first-line agents for CDI treatment are metronidazole and vancomycin, with the latter being the preferred agent in patients with severe disease as it has significantly superior efficacy. Expand
Fidaxomicin - the new drug for Clostridium difficile infection
  • C. Vaishnavi
  • Medicine
  • The Indian journal of medical research
  • 2015
TLDR
The bactericidal properties of fidaxomicin make it an ideal alternative for CDI treatment, but use should be considered taking into account the potential benefits of the drug, along with the medical requirements of the patient, the risks of treatment and the high cost of fidxomicin compared to other treatment regimens. Expand
Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection.
TLDR
The aim of this review is to summarize the available evidence for alternative treatment strategies for C. difficile disease and to make recommendations for their place in therapy. Expand
Clinical approach to severe Clostridium difficile infection: update for the hospital practitioner.
TLDR
Early surgical consultation is necessary in patients who do not respond to medical therapy or who demonstrate rising white blood cell counts or hemodynamic instability indicative of fulminant colitis, and it has been demonstrated that vancomycin is the more effective antibiotic in cases of severe disease. Expand
Impact of Clostridium difficile on inflammatory bowel
TLDR
Both vancomycin and metronidazole appear to be effective and treatment with oral vancomYcin is preferred in those with severe disease, including those who require hospitalization, and there is a need to prospectively examine whether CDI has long-term disease-modifying consequences inThose with underlying IBD. Expand
[Infections caused by Clostridium difficile].
TLDR
The aim of this review is to highlight the recent epidemiological data on CDIs and to provide an overview of the pathogenicity of the infection, diagnostic approaches, old and new treatment options, and current knowledge of infection control measures. Expand
Impact of Clostridium difficile on inflammatory bowel disease
TLDR
Both vancomycin and metronidazole appear to be effective and treatment with oral vancomYcin is preferred in those with severe disease, including those who require hospitalization, and there is a need to prospectively examine whether CDI has long-term disease-modifying consequences inThose with underlying IBD. Expand
Clostridium difficile infection: clinical spectrum and approach to management
  • C. Vaishnavi
  • Medicine
  • Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • 2011
TLDR
Adjunctive measures used for CDAD are probiotics and prebiotics, fecotherapy, adsorbents and immunoglobulin therapy, among the new therapies fidaxomicin has recently been approved by the American Food and Drugs Administration for treatment of CDAD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 114 REFERENCES
Treatment of Clostridium difficile infection.
  • D. Gerding, C. Muto, R. Owens
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
TLDR
Treatment algorithms are presented to help guide the management of patients with CDI, including a toxin-binding polymer, tolevamer; 2 poorly absorbed antimicrobials, OPT-80 and ramoplanin; monoclonal antibodies; and a C. difficile vaccine. Expand
Clostridium difficile: changing epidemiology and new treatment options
TLDR
The early recognition of Clostridrium difficile-associated diarrhoea caused by NAP1/027 is necessary to start rapid treatment, to prevent complications, and to prevent further spread of the bacterium. Expand
The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.
  • C. Surawicz, L. Mcfarland, +8 authors G. Elmer
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2000
TLDR
Comparison of data from this trial with data from previous studies indicates that recurrent CDD may respond to a short course of high- dose vancomycin or to longer courses of low-dose vancomYcin when either is combined with S. boulardii. Expand
Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease
TLDR
Data show that tapered or pulsed dosing regimens of vancomycin may result in a significantly better cure of RCDD, and the persistence of C. difficile spores suggests that additional strategies to restore the normal colonic microflora may also be beneficial. Expand
Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study
TLDR
Rifaximin has excellent in vitro activity against C. difficile, is well tolerated, and does not seem to promote development of resistance against enteric organisms; thus, it may be a therapeutic option for CDAD. Expand
Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.
TLDR
It is suggested that nitazoxanide may be as effective as vancomycin in treating CDI, in the first recent randomized controlled trial to compare any antimicrobial agent other than metronidazole with vancomYcin. Expand
Nitazoxanide for the treatment of Clostridium difficile colitis.
  • D. Musher, N. Logan, +4 authors J. Rossignol
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
TLDR
Nitazoxanide is at least as effective as metronidazole in treating C. difficile colitis, according to a prospective, randomized, double-blind study. Expand
Alternative treatments for Clostridium difficile disease: what really works?
TLDR
A review of current treatments for Clostridium difficile-associated disease and newer treatment strategies that take advantage of these mechanisms have been developed is described and the evidence for each strategy is examined. Expand
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.
TLDR
The findings suggest that metronidazole and vancomycin are equally effective for the treatment of mild CDAD, but vancomYcin is superior for treating patients with severe CDAD. Expand
[Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces].
TLDR
Treatment with donor faeces seems promising for patients who develop repeated recurrences despite adequate therapy and could be valuable in the future during (local) epidemics of the PCR ribotype 027 strain. Expand
...
1
2
3
4
5
...